|
Biotech Business
Click on article title to view & purchase. Articles are sorted by their publication date in reverse chronological order.
Total result: 415 articles |
 Page 3 of 6 
|
GENVAC VACCINE ENTERS HIV HUMAN THERAPEUTIC CLINICAL TRIALS.
October 01, 2006
BIRCH BARK COMPOUND MAY BE POTENT PROSTATE CANCER FIGHTER.
September 01, 2006
ACCENTIA TO LICENSE ALL MAYO ANTIFUNGALS FOR CHRONIC SINUSITIS.
September 01, 2006
AVI BIOPHARMA MODIFIES HEPATITIS C VIRUS CLINICAL STUDY.
September 01, 2006
ILYPSA COMPLETES PHASE 1 CLINICAL TRIAL OF ILY101.
June 01, 2006
FDA ACCEPTS ANTARES LICENSEE'S NDA FOR BIO-E-GEL.
June 01, 2006
AXONYX REPORTS GOOD EFFECTS OF PHENSERINE ON ALZHEIMERS'.
June 01, 2006
NYMOX REPORTS POSITIVE SAFETY DATA FOR PHASE 2 NX-1207 TRIAL.
June 01, 2006
ACCREDO SIGNS 5-YEAR SPECIALTY PHARMACY PACT FOR FLOLAN.
June 01, 2006
TENASCIN-C HELPS DIRECT CLOT-INDUCED NEOVASCULARIZION.
May 01, 2006
SPHERIX MOVES TOWARD FINAL DIABETES TRIALS.
May 01, 2006
ORPHAN THERAPEUTICS COMPLETES ENROLLMENT FOR TERLIPRESSIN.
May 01, 2006
DATA SHOWS 2ME2 POTENTIAL AS ANTI-RHEUMATOID DRUG.
May 01, 2006
TARGET DISCOVERY/VIRGINIA PROSTATE DEVELOP CLINICAL ASSAYS.
May 01, 2006
GERON LICENSES MAXCYTE CELL LOADING TECHNOLOGY.
April 01, 2006
NORTHFIELD RESPONDS TO REPORTS ABOUT ITS PHASE III TRIAL.
April 01, 2006
GENITOPE INITIATES TRIAL TO EVALUATE MYVAX FOR LEUKEMIA.
April 01, 2006
AVECIA/TRILINK SCALE-UP OLIGONUCLEOTIDE MANUFACTURING.
April 01, 2006
NASTECH COMPLETES FDA PAI FOR CALCITONIN-SALMON MANUFACTURE.
April 01, 2006
ENTREMED COMMENCES PHASE 2 STUDY FOR PANZEM NCD.
March 01, 2006
BAYER UNVEILS KOGENATE FS WITH BIO-SET FOR HEMOPHILIA A.
March 01, 2006
NYMOX TO PRESENT ALZHEIMALERT POSITIVE FINDINGS.
March 01, 2006
PROLX INITIATES PHASE 1B TRIAL FOR THIOREDOXIN INHIBITOR PX-12.
March 01, 2006
BIOPAL ANNOUNCES NEXT-GENERATION KIDNEY DIAGNOSTIC ASSAYS.
March 01, 2006
GUANILIB DRUG CANDIDATE FOR GI DISEASE MOVES TO CLINICAL TRIAL.
February 01, 2006
DURECT GETS POSITIVE RESULTS FROM TRANSDERMAL SUFENTANIL PATCH.
February 01, 2006
ANADYS INITIATES 28-DAY CLINICAL TRIAL OF ANA975.
February 01, 2006
BIOCRYST INITIATES INTRAVENOUS PHASE I/II OF FODOSINE.
February 01, 2006
FDA ACCEPTS ENTREMED IND FOR ENMD-1198 ANTITUMOR AGENT.
January 01, 2006
ALEXION REPORTS PHASE III RESULTS FOR PRIMO-CABG2 TRIAL.
January 01, 2006
ADHEREX GETS NEW DRUG IND CLEARANCE FOR ENILURACIL.
January 01, 2006
SEATTLE GENETICS EXPANDS SGN-40 PROGRAM FOR LEUKEMIA.
January 01, 2006
ALNYLAM SUBMITS IND APPLICATION FOR ALN-RSV01 TRIAL.
December 01, 2005
PALL PRION PROTECTS BLOOD SUPPLY FROM VARIANT CJD.
December 01, 2005
PROVENGE EXTENDS SURVIVAL IN PATIENTS WITH PROSTATE CANCER.
December 01, 2005
XANTHUS INITIATES PHASE 2 STUDY OF XANAFIDE FOR AML.
December 01, 2005
GILEAD/ACHILLION INITIATE GS 9132 PHASE I CLINICAL TRIAL.
November 01, 2005
BARRIER REPORTS POSITIVE PHASE 2A DATA FOR ORAL RAMBAZOLE.
November 01, 2005
DIOSYNTH AMENDS NEOPHARM'S VALIDATION/MANUFACTURING PACT.
November 01, 2005
LIFE SCIENCES AWARDED PATENT FOR COMPONENTS OF CANCER TEST.
November 01, 2005
BARRIER RETAINS WORLDWIDE RIGHTS TO HYPHANOX.
November 01, 2005
FORTICAL NASAL SPRAY FOR OSTEOPOROSIS LAUNCHED.
October 01, 2005
ARIAD GETS ORPHAN DRUG DESIGNATION FOR AP23573.
October 01, 2005
CELERA GENOMICS/SEATTLE GENETICS SELECT CANCER TARGET.
October 01, 2005
FDA APPROVES LIGAND'S AVINZA.
October 01, 2005
LABOTHERM/PURDUE PHARMA SIGN TRAMADOL PACT.
October 01, 2005
CYLENE INITIATES PHASE I CLINICAL TRIAL FOR CX-3543.
September 01, 2005
DOR BIOPHARMA/CAMBREX ACHIEVE RIVAX MILESTONE.
September 01, 2005
MYOGEN COMPLETES ENROLLMENT FOR PHASE 3 ARIES-2 TRIAL.
September 01, 2005
EXELIXIS INITIATES PHASE I CLINICAL TRIAL FOR ANTICANCER XL820.
September 01, 2005
CEPHALON/ALKERMES SIGN PACT TO DEVELOP VIVITREX.
August 01, 2005
AVANIR INITIATES PHASE III CLINICAL TRIAL OF NEURODEX.
August 01, 2005
DYNAVAX INITIATES PHASE 3 TRIAL FOR HEPATITIS B VACCINE.
August 01, 2005
PPD LICENSES GGTASE INHIBITOR COMPOUNDS TO DUKE UNIVERSITY.
August 01, 2005
GENVEC GETS FDA CLEARANCE TO RESUME PHASE II TNFERADE TRIAL.
July 01, 2005
ALNYLAM INITIATES RNAI THERAPEUTIC PROGRAM FOR PANDEMIC FLU.
July 01, 2005
ZIOPHARM INITIATES 2ND PHASE I STUDY OF ZIO-101.
July 01, 2005
MARC GETS U.S. PATENT FOR BETULINOL DERIVATIVES FOR CANCER.
July 01, 2005
THRESHOLD GETS POSITIVE RESULTS FROM TH-070 PHASE 2 BPH TRIAL.
July 01, 2005
INFINITY'S IPI-504 PROVIDES PROMISING ANTICANCER ACTIVITY.
June 01, 2005
NUVELO BEGINS PHASE 3 TRIAL OF ALFIMEPRASE FOR "LEG ATTACK".
June 01, 2005
GLYCOFI/CENTOCOR EVALUATE GLYCOPROTEIN PRODUCTION.
June 01, 2005
MAP PHARMACEUTICALS APPOINTS NELSON PRESIDENT/CEO.
June 01, 2005
BOLEX/CENTOCOR TO MANUFACTURE PROTEINS USING LEX SYSTEM.
May 01, 2005
FDA ACCEPTS XYREM SNDA FOR REVIEW.
May 01, 2005
IKONISYS SIGNS LICENSE/SUPPY PACTS WITH ABBOTT.
May 01, 2005
BIOMARKER BEGINS PILOT STUDY OF BREAST CANCER BLOOD TEST.
May 01, 2005
LIAD SCIENTISTS IDENTIFY BACTERIA TRIGGERING IMMUNE RESPONSE.
May 01, 2005
PATENT AWARDED TO UNIGEN FOR NOVEL POLICOSANOL.
March 01, 2005
ORPHAN MEDICAL SUBMITS XYREM SNDA TO FDA.
March 01, 2005
COTHERIX SELECTS ACCREDO THERAPEUTICS TO DISTRIBUTE VENTAVIS.
March 01, 2005
IGC EXPO RELEASES GENE PROFILES FOR 60 TUMOR SPECIMENS.
March 01, 2005
MORPHOSYS EXTENDS AGREEMENT WITH CENTOCOR.
February 01, 2005
RIGEL INITIATES R406 CLINICAL TRIAL FOR RHEUMATOID ARTHRITIS.
February 01, 2005
GENZYME FILES FOR EUROPEAN APPROVAL OF MYOZYME.
February 01, 2005
|
